TY - JOUR
T1 - Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
AU - Vichaya, Elisabeth G.
AU - Wang, Xin Shelley
AU - Boyette-Davis, Jessica A.
AU - Mendoza, Tito R.
AU - He, Zijing
AU - Thomas, Sheeba K.
AU - Shah, Nina
AU - Williams, Loretta A.
AU - Cleeland, Charles S.
AU - Dougherty, Patrick M.
N1 - Funding Information:
Acknowledgments The authors wish to acknowledge Jackie Joy and Venus Ilagan for symptom and clinical data collection, Tina Peters and Tony Perez for QST data collection, Gary Mobley and Katherine Gilmore for data management, and Jeanie F. Woodruff, ELS for editorial assistance. This work was supported by the National Cancer Institute at the US National Institutes of Health (CA124787 and NS046606). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
PY - 2013/6
Y1 - 2013/6
N2 - Purpose: Chemotherapy-induced peripheral neuropathy is a major complication in the treatment for cancer, including multiple myeloma (MM). Patients may develop painful and non-painful (e.g., numbness) neuropathy symptoms that impair function and often persist after therapy is terminated. This study tested the hypothesis that baseline subclinical neuropathy, as assessed by sensory thresholds, is related to the development of neuropathy symptoms (e.g., pain and numbness) in patients with MM undergoing treatment with chemotherapy. Methods: Patients (n = 56) who had undergone two or fewer cycles of induction therapy and who had no evident neuropathy were assessed using quantitative sensory tests to determine multiple-modality sensory thresholds. Patient-reported pain and numbness were assessed through induction therapy (16 weeks) via the MD Anderson Symptom Inventory. A subset of participants (n = 15) continued reporting on their symptoms for an additional 16 weeks ("maintenance phase"). Results: Patients with sharpness detection deficits at baseline (n = 11, 20 % of sample) reported less severe pain and numbness during induction therapy and less numbness during maintenance therapy (P < 0.05). During the maintenance phase, patients with warmth detection deficits (n = 5, 38 % of sample) reported more severe pain and numbness, and those with skin temperature deficits (n = 7, 47 % of maintenance sample) reported more severe pain (P < 0.05). These deficits were related to patient reported difficulty walking, a common symptom of peripheral neuropathy. Conclusion: Our results suggest that baseline subclinical sensory deficits may be related to a patient's risk for developing chemotherapy-induced peripheral neuropathy.
AB - Purpose: Chemotherapy-induced peripheral neuropathy is a major complication in the treatment for cancer, including multiple myeloma (MM). Patients may develop painful and non-painful (e.g., numbness) neuropathy symptoms that impair function and often persist after therapy is terminated. This study tested the hypothesis that baseline subclinical neuropathy, as assessed by sensory thresholds, is related to the development of neuropathy symptoms (e.g., pain and numbness) in patients with MM undergoing treatment with chemotherapy. Methods: Patients (n = 56) who had undergone two or fewer cycles of induction therapy and who had no evident neuropathy were assessed using quantitative sensory tests to determine multiple-modality sensory thresholds. Patient-reported pain and numbness were assessed through induction therapy (16 weeks) via the MD Anderson Symptom Inventory. A subset of participants (n = 15) continued reporting on their symptoms for an additional 16 weeks ("maintenance phase"). Results: Patients with sharpness detection deficits at baseline (n = 11, 20 % of sample) reported less severe pain and numbness during induction therapy and less numbness during maintenance therapy (P < 0.05). During the maintenance phase, patients with warmth detection deficits (n = 5, 38 % of sample) reported more severe pain and numbness, and those with skin temperature deficits (n = 7, 47 % of maintenance sample) reported more severe pain (P < 0.05). These deficits were related to patient reported difficulty walking, a common symptom of peripheral neuropathy. Conclusion: Our results suggest that baseline subclinical sensory deficits may be related to a patient's risk for developing chemotherapy-induced peripheral neuropathy.
KW - Bortezomib
KW - Multiple myeloma
KW - Patient-reported outcome
KW - Peripheral neuropathy
KW - Quantitative sensory testing
UR - http://www.scopus.com/inward/record.url?scp=84878644815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878644815&partnerID=8YFLogxK
U2 - 10.1007/s00280-013-2152-7
DO - 10.1007/s00280-013-2152-7
M3 - Article
C2 - 23543296
AN - SCOPUS:84878644815
SN - 0344-5704
VL - 71
SP - 1531
EP - 1540
JO - Cancer chemotherapy and pharmacology
JF - Cancer chemotherapy and pharmacology
IS - 6
ER -